Boreal Capital Management’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Boreal Capital Management's CADL Position: Q3 2026 in Review
Boreal Capital Management held its Candel Therapeutics (CADL) position steady in Q3 2026 at 8,000 shares worth $83.5K. The position accounts for 0.06% of the portfolio, ranked #152.
Boreal Capital Management first reported a position in CADL in Q2 2025 and has held it in 6 quarters since. The position peaked at $90.4K in Q4 2025. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Boreal Capital Management held 8,000 shares of Candel Therapeutics worth $83.5K as of Q3 2026.
- Boreal Capital Management left its Candel Therapeutics share count unchanged in Q3 2026.
- Candel Therapeutics made up 0.06% of Boreal Capital Management's portfolio in Q3 2026, its #152 holding.
- Boreal Capital Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 6 quarters since.
- Boreal Capital Management's Candel Therapeutics position peaked at $90.4K in Q4 2025.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Boreal Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.